HIV Medicine

• Active Tuberculosis and Mycobacterium tuberculosis Latent Infection in Patients with HIV/AIDS This study from Brazil uncovered missed opportunities for preventing TB in patients with HIV/AIDS and suggests effective ways to lower TB rates in this population.
  HIV Medicine, October 2009
• Discordance in HIV-1 Viral Loads and Antiretroviral Drug Concentrations Comparing Semen and Blood Plasma When a male patient has undetectable plasma viral loads thanks to HAART, is he sexually noninfectious? Maybe not, if the drugs aren't penetrating to his genital tract.
  HIV Medicine, October 2009
• Boosted Protease Inhibitors as a Therapeutic Option in the Treatment of HIV-Infected Children This review provides a guide to the multiple options that boosted PI regimens offer for both treatment-naïve and treatment-experienced children across a range of ages.
  HIV Medicine, October 2009
• Effects of Nucleoside Reverse Transcriptase Inhibitor Backbone on the Efficacy of First-Line Boosted Highly Active Antiretroviral Therapy Based on Protease Inhibitors Tenofovir/emtricitabine and abacavir/lamivudine are widely used with ritonavir-boosted protease inhibitors as first-line HAART. Is one better than the other?
  HIV Medicine, October 2009
• Long-Term Follow-Up of Nevirapine-Treated Patients in a Single-Center Cohort This study reviewed the safety and efficacy of nevirapine-based therapy in patients at a single clinic who have initiated NVP-containing combined antiretroviral therapy since 1994.
  HIV Medicine, September 2009
• Trends in Mortality and Antibiotic Resistance Among HIV-Infected Patients With Invasive Pneumococcal Disease Has the HAART era brought a reduction in the burden of invasive pneumococcal disease?
  HIV Medicine, September 2009
• How Reliable Is an Undetectable Viral Load? These researchers have calculated the approximate reliability of undetectable viral loads according to cut-off points, and identified the most important factor predicting reliability.
  HIV Medicine, September 2009
• Tenofovir-Associated Renal and Bone Toxicity This study describes the clinical presentation and renal and bone abnormalities related to treatment with tenofovir, and recommends screening for tenofovir-related toxicity.
  HIV Medicine, September 2009
• Uptake of and Virological Response to Antiretroviral Therapy Among HIV-infected Former and Current Injecting Drug Users and Persons in an Opiate Substitution Treatment Programme: The Swiss HIV Cohort Study Uptake of ART and virological response to it differs between current injecting drug users and those whove kicked the habit.
  HIV Medicine, August 2009
• Reductions in HIV Transmission Risk Behavior Following Diagnosis of Primary HIV Infection: A Cohort of High-Risk Men Who Have Sex With Men The particularly high infectivity of primary HIV infection makes even transient risk reduction particularly valuable. How effective is counseling in this situation?
  HIV Medicine, August 2009
• Tenofovir Disoproxil Fumarate in Pregnancy and Prevention of Mother-to-Child Transmission of HIV-1: Is it Time to Move on from Zidovudine? Although zidovudine remains the cornerstone for preventing mother-to-child transmission of HIV-1, single-dose tenofovir disoproxil fumarate during delivery may offer an additional advantage.
  HIV Medicine, August 2009
• Suboptimal CD4 Recovery on Long-Term Suppressive Highly Active Antiretroviral Therapy Is Associated with Favorable Outcome Many HIV-positive patients with long-term viral suppression have suboptimal CD4 recovery but higher markers of immune maturation and activationand low morbidity and mortality.
  HIV Medicine, August 2009
• Mortality is Influenced by Locality in a Major HIV/AIDS Epidemic An increase was seen in the risk of death among HIV-infected people on HAART in a neighborhood with a high concentration of injecting drug users relative to one with a high concentration of gay men.
  HIV Medicine, May 2009
• Comparison of Glomerular Filtration Rate Estimates vs. 24-h Creatinine Clearance in HIV-positive Patients HIV/AIDS clinicians should be aware of the differences between measured and predicted CrCl and GFR results, in order to interpret them critically and make the most appropriate care decisions.
  HIV Medicine, April 2009
• Short-term Antiretroviral Therapy To Prevent Mother-to-child Transmission Is Safe and Results in a Sustained Increase in CD4 T-cell Counts in HIV-1-infected Mothers Read about the results of a 5-year cohort study involving HIV-1-infected pregnant women who had received START to prevent mother-to-child transmission.
  HIV Medicine, March 2009
• Liver Enzyme Elevation After Lamivudine Withdrawal in HIV-hepatitis B Virus Co-infected Patients: The Swiss HIV Cohort Study Is HBV reactivation, leading to liver dysfunction, an under-reported consequence of 3TC withdrawal in HIV-HBV co-infected patients?
  HIV Medicine, January 2009
• Ankle-branch Index and HIV: The Role of Antiretrovirals Is altered ABI associated with protease inhibitor use independently of dyslipidaemia?
  HIV Medicine, January 2009
• The Associations Between Age and the Development of Laboratory Abnormalities and Treatment Discontinuation for Reasons Other Than Virological Failure in the First Year of HAART Learn how improving the tolerability of HAART regimens will help sustain good outcomes in all age group.
  HIV Medicine, January 2009
• Factors Associated With Viral Rebound Among Highly Treatment-experienced HIV-positive Patients who Have Achieved Viral Suppression Are rebound rates reduced substantially if highly treatment-experienced patients can maintain viral suppression?
  HIV Medicine, January 2009
• British HIV Association Guidelines for Immunization of HIV-Infected Adults 2008 The British HIV Association presents guidelines for the immunization of HIV-infected adults -- do they differ from U.S. guidelines?
  HIV Medicine, November 2008